Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4945-4952

  Shiraishi, Kouya ^a   Kohno, Takashi ^a   Tanai, Chiharu ^a   Goto, Yasushi ^a   Kuchiba, Aya ^a   Yamamoto, Seiichiro ^a   Tsuta, Koji ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a   Yokota, Jun ^a   Kunitoh, Hideo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; NEDAPLATIN; PACLITAXEL;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CHEMOTHERAPY; DNA POLYMORPHISM; DNA REPAIR; FEMALE; GENE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLATINUM BASED DOUBLET CHEMOTHERAPY; POLY(ADP RIBOSE) POLYMERASE 1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 79951875424     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.5334     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Goffin J, Lacchetti C, Ellis PM, et al: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. J Thorac Oncol 5:260-274, 2010
3. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small- cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323, 2007 (Pubitemid 46323100)
4. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002 (Pubitemid 35266288)
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
6. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006 (Pubitemid 44343542)
7. Camps C, Sirera R, Iranzo V, et al: Gene expression and polymorphisms of DNA repair enzymes: Cancer susceptibility and response to chemotherapy. Clin Lung Cancer 8:369-375, 2007 (Pubitemid 46924057)
8. Wei SZ, Zhan P, Shi MQ, et al: Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis. Med Oncol [epub ahead of print on February 9, 2010]
9. Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601, 2004 (Pubitemid 41103746)
10. Isla D, Sarries C, Rosell R, et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin- treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-1203, 2004 (Pubitemid 39199306)
11. de las Peñas R, Sanchez-Ronco M, Alberola V, et al: Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668-675, 2006
12. Giachino DF, Ghio P, Regazzoni S, et al: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13:2876-2881, 2007 (Pubitemid 46849561)
13. Matakidou A, el Galta R, Webb EL, et al: Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 16:2333-2340, 2007 (Pubitemid 47423899)
14. Wu X, Lu C, Ye Y, et al: Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18:955-965, 2008
15. Sakiyama T, Kohno T, Mimaki S, et al: Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 114:730-737, 2005 (Pubitemid 40344434)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Travis W, Colby, TV, Corrin, B, et al: Histological Typing of Lung and Pleural Tumors (ed 3). Heidelberg, Germany, Springer-Verlag, 1999
18. Brambilla E, Travis WD, Colby TV, et al: The new World Health Organization classification of lung tumours. Eur Respir J 18:1059-1068, 2001
19. Kawaishi M, Fujiwara Y, Fukui T, et al: Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4:208-213, 2009
20. Sekine I, Nokihara H, Horiike A, et al: Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 90:1125-1128, 2004 (Pubitemid 38496801)
21. Shiraishi K, Kohno T, Kunitoh H, et al: Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis 30:65-70, 2009
22. Breslow NE, Day NE: Statistical methods in cancer research: Volume I - The analysis of casecontrol studies. IARC Scientific Publication No. 32, 1980, pp 5-338
23. Weston A, Perrin LS, Forrester K, et al: Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1:481-483, 1992
24. Dumont P, Leu JI, Della Pietra AC 3rd, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365, 2003 (Pubitemid 36278852)
25. Bergamaschi D, Gasco M, Hiller L, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402, 2003 (Pubitemid 38340307)
26. Vikhanskaya F, Siddique MM, Kei Lee M, et al: Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res 11:4348-4356, 2005 (Pubitemid 40825623)
27. The International Agency for Research on Cancer: IARC TP53 Database. http://www-p53.iarc.fr/
28. Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 26:882-893, 2004 (Pubitemid 39128102)
29. Iglehart JD, Silver DP: Synthetic lethality: A new direction in cancer-drug development. N Engl J Med 361:189-191, 2009
30. Jacob DA, Bahra M, Langrehr JM, et al: Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 22:738-748, 2007 (Pubitemid 46608375)
31. Cao WH, Wang X, Frappart L, et al: Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients. Mutat Res 632:20-28, 2007 (Pubitemid 47031684)
32. Gandara DR, Kawaguchi T, Crowley J, et al: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J Clin Oncol 27:3540-3546, 2009
33. Bosch TM: Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 448:63-76, 2008